Literature DB >> 10189362

Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure.

T Meguro1, C Hong, K Asai, G Takagi, T A McKinsey, E N Olson, S F Vatner.   

Abstract

Left ventricular hypertrophy (LVH) is a compensatory mechanism to cope with pressure overload. Recently, a calcineurin pathway mediating LVH and its prevention by cyclosporine was reported. We examined whether calcineurin mediates LVH due to pressure overload in mice. Pressure overload was induced by aortic banding in 53 mice (32 treated with cyclosporine [25 mg. kg-1. d-1], 21 treated with vehicle). There were 17 sham-operated mice (9 treated with vehicle, 8 treated with cyclosporine). At 3 weeks after surgery, LV weight to body weight was greater in the nontreatment banded group (4.39+/-0. 16 mg/g) than in the cyclosporine-treated banded group (3.95+/-0.14 mg/g, P<0.05), with both groups being greater compared with the entire group of sham-operated mice (3.02+/-0.04 mg/g). The pressure gradient between the ascending and abdominal aorta was not different between the cyclosporine-treated (49.6+/-6.1 mm Hg) and nontreatment groups (48.7+/-4.6 mm Hg). Although LV systolic pressure was lower in the cyclosporine-treated banded animals, LV systolic wall stress was similar in the nontreatment banded group and in the cyclosporine-treated group. However, LV dP/dt was lower (P=0.05) in the cyclosporine-treated banded group (4774+/-656 mm Hg/s) than in the nontreatment banded group (6604+/-516 mm Hg/s). During the protocol, 23 of 32 mice in the cyclosporine-treated group and 9 of 21 mice in the nontreatment group died. All deaths occurred within 10 days after surgery. Deaths caused by heart failure were 7.2-fold higher (P<0.05) in the cyclosporine-treated group, whereas deaths due to other causes were not different between the 2 groups. In addition, LV function of mice was assessed at 48 hours after banding; LV ejection fraction measured with echocardiography was lower (P<0.05) in the cyclosporine-treated banded group (66+/-3.0%) than in the nontreatment banded group (79+/-1.5%), whereas LV systolic wall stresses were similar. Calcineurin phosphatase activity was depressed similarly in both cyclosporine-treated groups compared with both nontreatment groups. Thus, cyclosporine could attenuate, but not prevent, LVH at the expense of inhibiting an important compensatory mechanism in response to pressure overload, resulting in reduced LV wall stress and function and increased susceptibility to decompensation and heart failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189362     DOI: 10.1161/01.res.84.6.735

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  46 in total

Review 1.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.

Authors:  K R Chien
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Calcineurin inhibition and cardiac hypertrophy: a matter of balance.

Authors:  L A Leinwand
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

Review 4.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

5.  Calcium handling proteins: structure, function, and modulation by exercise.

Authors:  Jamille Locatelli; Leonardo V M de Assis; Mauro C Isoldi
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

6.  Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant.

Authors:  Rashmi Choudhary; K P Mishra; C Subramanyam
Journal:  Indian J Clin Biochem       Date:  2006-09

Review 7.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

8.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.

Authors:  B A Rothermel; T A McKinsey; R B Vega; R L Nicol; P Mammen; J Yang; C L Antos; J M Shelton; R Bassel-Duby; E N Olson; R S Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

9.  Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.

Authors:  L J De Windt; H W Lim; O F Bueno; Q Liang; U Delling; J C Braz; B J Glascock; T F Kimball; F del Monte; R J Hajjar; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

10.  The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.

Authors:  Junichi Sadoshima; Olivier Montagne; Qian Wang; Guiping Yang; Jill Warden; Jing Liu; Gen Takagi; Vijaya Karoor; Chull Hong; Gary L Johnson; Dorothy E Vatner; Stephen F Vatner
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.